Pharmaceutical compositions of levoamlodipine and atorvastatin

Abstract

The invention relates to a pharmaceutical composition of Levamlodipine or its medicinal salts and addition salts with Atorvastatin or its medicinal salts, and the use of the pharmaceutical composition in preparing medicament for treating mixed type hypertension and lipidemia.

Description

technical field [0001] The present invention relates to a pharmaceutical composition of levamlodipine or its pharmaceutically acceptable salt and addition salt and atorvastatin or its pharmaceutically acceptable salt, and the preparation of the pharmaceutical composition for treating mixed hypertension and hypertensive Application in lipidemia drugs. technical background [0002] Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, and the conversion of HMG-CoA to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by reductase, and inhibin can inhibit HMG-CoA reductase from catalyzing the conversion reaction. Therefore, HMG-CoA reductase inhibitors are effective lipid-lowering agents. [0003] Atorvastatin is a HMG-CoA reductase inhibitor. It itself is inactive, and the hydrolyzate after oral absorption competitively inhibits the rate-limiting enzyme hydroxymethylg...

AI Technical Summary

Problems solved by technology

[0006] The patent CN1268052A "therapeutic composition containing amlodipine and atorvastatin" applied by Pfizer of the United States in China, and the CN1117566C "combined drug form containing amlodipine and statin compounds" applied by Pfizer Products Company of the United States, To a certain extent, it expounds the application of compound preparations containing racemic amlodipine in various cardiovascular diseases, but it does not clearly show the superiority brought by this combination of drugs